Our amendment LIB-1 regarding article 40 is actually the result of some conversations we had with both the generics and the innovative medicines. We came up with what I know is an accepted compromise between those two stakeholders, so we're hoping it's acceptable to the committee as well. It does address some of the problems in section 62, but I think it addresses them with a more balanced approach than did the previous amendment.
On December 14th, 2016. See this statement in context.